

# Gene Therapy: Implications for Pharmacy Practice

John Petrich, RPh, MS  
Investigational Drug Service Manager  
Cleveland Clinic

## Disclosures

- I have not been bribed
- I have not been corrupted
- I have no hidden alliances with rich people
- My motives are pure

## Learning Objectives

- Define the foundation and general principles of gene therapy
- Review practices and handling of gene therapy products
- Describe issues that pharmacists should address now and in the future

Gene therapy involves the introduction of genetic material into an individual, or the modification of the individual's genetic material, in order to achieve a therapeutic objective

The World Health Organization

## Therapeutic options

- Single genetic conditions
- Multifactorial genetic conditions
- Acquired genetic conditions

## Vectors

- Viral
- Liposomal
- Artificial Chromosomal
- Other nucleic acid (plasmid, RNA technology)

## Viral vectors

- Retrovirus
- Adenovirus
- Adeno-associated virus

Vector	Advantages	Disadvantages
Adenovirus	High transfection efficiency in vivo and ex vivo Can infect dividing and nondividing cells Wide host cell range	Limited insert size capacity Short duration of expression Immunogenic (repeat dosing therefore ineffective)
Retrovirus	No immune response Reasonable duration of expression Integrates into host cell genome High transfection efficiency ex vivo	Only infects dividing cells Limited insert size capacity Potential safety risk of insertional mutagenesis
Adeno-associated virus	Can infect dividing and nondividing cells Reasonable duration of expression Low immunogenicity	Inefficient large scale virus production Very limited insert size capacity

## Technical Limitations

- Identification
- Manufacturing
- Introduction
- Expression

## Patient Safety

- Toxicity
- Fatality
- Interactions
- Latent effects

## Ethics

- Selection
- Repair versus improvement
- Consequences

## Follow-up

## Biosafety Levels

- Biosafety Level 1
- Biosafety Level 2
- Biosafety Level 3
- Biosafety Level 4

## Biosafety Level 2

- Standard Microbiological Practices
- Special Practices
- Safety Equipment
- Laboratory Facilities (Secondary Barriers)

[www.cdc.gov](http://www.cdc.gov)

## Biosafety Level 2

- **Standard Microbiological Practices**
- Special Practices
- Safety Equipment
- Laboratory Facilities (Secondary Barriers)

## Biosafety Level 2

- Standard Microbiological Practices
- **Special Practices**
- Safety Equipment
- Laboratory Facilities (Secondary Barriers)

## Biosafety Level 2

- Standard Microbiological Practices
- Special Practices
- **Safety Equipment**
- Laboratory Facilities (Secondary Barriers)

## Biosafety Level 2

- Standard Microbiological Practices
- Special Practices
- Safety Equipment
- **Laboratory Facilities (Secondary Barriers)**

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- Disposal
- Decontamination of spills
- Accidental exposure

## Pharmacy Handling

- **Receipt and storage**
- Preparation
- Dispensing
- Disposal
- Decontamination of spills
- Accidental exposure

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- Disposal
- Decontamination of spills
- Accidental exposure

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- Disposal
- Decontamination of spills
- Accidental exposure

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- **Disposal**
- Decontamination of spills
- Accidental exposure

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- Disposal
- **Decontamination of spills**
- Accidental exposure

## Pharmacy Handling

- Receipt and storage
- Preparation
- Dispensing
- Disposal
- Decontamination of spills
- **Accidental exposure**

## Conclusion

- Increased availability leads to increase in knowledge
- Increased knowledge leads to decreased uncertainty.
- Decreased uncertainty leads to confidence to select the appropriate level of caution
- Advisory Group on Gene Therapy

## References

1. Collaboration TA. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care*. 2003 Feb;12(1):18-23.
2. Research ACoH. Genomics and World Health: Report of the Advisory Committee on Health Research. Geneva: World Health Organization; 2002.
3. U.S. Department of Health and Human Services Public Health Service, National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4e ed. Washington, DC: U.S. Government Printing Office; 1999.
4. Roth RI, Fleischer NM. Gene therapy: applications to pharmacy practice. *J Am Pharm Assoc (Wash)*. 2002 Sep-Oct;42(5):692, 4-8.
5. The Medicines for Human Use (Clinical Trials) Regulations 2004. 1031; 2004.
6. EAHP Guidance on the Pharmacy Handling of Gene Medicines, 2007.
7. Armistead J, Zillich A, Williams K, Sitzlar S, Wermeling D. Hospital and Pharmacy Departmental Policies and Procedures for Gene Therapy at a Teaching Institute. *Hospital Pharmacy*. 2001;36:56-66.
8. Stoner NS, Gibson RN, Edwards J. Development of procedures to address health and safety issues in the administration of gene therapy within the clinical setting *J Oncol Pharm Practice*. 2003;9:29-35.

## References

9. DeCederfelt HJ, Grimes GJ, Green L, DeCederfelt RO, Daniels CE. Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department. *Am J Health Syst Pharm*. 1997 Jul 15;54(14):1604-10.
10. Power LA, Anderson RW, Cortopassi R, Gera JR, Lewis RM, Jr. Update on safe handling of hazardous drugs: the advice of experts. *Am J Hosp Pharm*. 1990 May;47(5):1050-60.
11. U.S. Department of Health and Human Services Public Health Service, National Institutes of Health. Primary Containment for Biohazards: Selection, Installation and Use of Biological Safety Cabinets. Washington, DC: U.S. Government Printing Office; 1995.
12. McCormick L, Maheshwari G. Inactivation of adenovirus types 5 and 6 by Virkon S. *Antiviral Res*. 2004 Oct;64(1):27-33.
13. Sauerbrei A, Sehr K, Eichhorn U, Reimer K, Wutzler P. Inactivation of human adenovirus genome by different groups of disinfectants. *J Hosp Infect*. 2004 May;57(1):67-72.
14. Wutzler P, Sauerbrei A. Virucidal efficacy of a combination of 0.2% peracetic acid and 80% (v/v) ethanol (PAA-ethanol) as a potential hand disinfectant. *J Hosp Infect*. 2000 Dec;46(4):304-8.